You are here

Article Text

Article menu
Download PDFPDF
Structured abstracts of sentinel articles: Picket
Rituximab is more effective than tacrolimus in steroid-dependent nephrotic syndrome
  1. Nicole Solomon1,
  2. Alex D Lalayiannis2
  1. 1 Paediatric Nephrology, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, UK
  2. 2 Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
  1. Correspondence to Dr Alex D Lalayiannis, Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK; alex.lalayiannis{at}nhs.net

http://dx.doi.org/10.1136/archdischild-2018-316537

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Study design

    Design: Single-centre, open-label, two parallel-arm phase 3 randomised comparative study.1

    Allocation: All consecutive eligible patients were randomly allocated to receive either rituximab or tacrolimus along with alternate-day prednisolone over a 12-month period.

    Blinding: Blinding was not undertaken.

    Study question

    Setting: Patients were recruited from a single centre in Sealdah, Kolkata, India.

    Patients: All patients aged 3–16 years with steroid-dependent nephrotic syndrome (SDNS) attending the study centre with estimated glomerular filtration rate >80 mL/min/1.73 m2. The participants were in remission with no proteinuria and no previous exposure to a corticosteroid sparing agent, and a secondary form of nephrotic syndrome and active infection had been excluded. All participants had a kidney biopsy 3 months prior to enrolment.

    Intervention: Following randomisation, children received either oral tacrolimus for 12 months or a course of rituximab infusions:

    Tacrolimus: 0.2 mg/kg/day (target trough levels of 5–7 ng/mL).

    Rituximab: Two to …

    View Full Text

    Footnotes

    • Contributors NS and ADL coauthored the abstract and commentary.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Patient consent for publication Not required.